Sixteen RCTs [7, 8, 18–31] including 38,335 patients with type 2 diabetes mellitus (20,914 patients who received SGLT2 inhibitors and 17,421 patients with placebo) matched our predefined inclusion criteria and were included in the final meta-analysis (Fig. 1). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.